Growth in the HLA typing market is mainly driven by factors such as the increasing number of HLA typing procedures conducted, technological advancements in the field of HLA typing, and increasing funding for research.
The global HLA typing market is projected to reach USD 1.7 billion by 2025 from USD 1.2 billion in 2019, at a CAGR of 5.9%.
However, the high costs of HLA typing products and limited reimbursements for target procedures are expected to restrain market growth in the coming years. Along with this, the significant supply-demand gap between the number of organ donors and organs required annually is expected to challenge market growth to a certain extent.
By product and service, reagents & consumables accounted for the largest market share in 2019.
On the basis of product & service, the HLA typing market has been segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment accounted for the largest share of the HLA typing market in 2019. The segment is expected to register the highest growth in the same year. Factors such as the growing application horizons of molecular assay techniques in HLA typing, increasing patient emphasis on effective and early patient profiling during organ transplantation, the growing adoption of molecular diagnostic techniques in research studies, and the rising number of target procedures across major markets are driving the growth of this segment.
Based on technology, the molecular assay technologies segment accounted for the largest share in 2019.
On the basis of technology, the HLA typing market is segmented into molecular and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest share of the HLA typing market in 2019. The growth of this segment is attributed to their benefits over non-molecular assays, such as low turnaround times, high procedural efficacy, multi-sample study capabilities, and real-time sample analysis.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39129877
The diagnostic applications segment will continue to dominate the HLA typing market in 2025.
On the basis of application, the HLA typing market is segmented into diagnostic and research applications. The diagnostic applications segment dominated the HLA typing market in 2018. This is attributed to technological advancements in molecular assay techniques, the increasing adoption of molecular assay procedures for pathogen encounter detection and histocompatibility cross-matching, and the growing incidence of chronic and infectious diseases.
The commercial service providers segment accounted for the largest share of the HLA typing market in 2019.
On the basis of end user, the HLA typing market is segmented into commercial service providers, hospitals & surgical centers, and research laboratories & academic institutes. In 2019, the commercial service providers segment accounted for the largest share of the HLA typing market due to the rapid modernization and adoption of automation in HLA typing, growing outsourcing of R&D activities to said providers, and the increasing consolidation of diagnostic laboratories.
The market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period.
The HLA typing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period, primarily due to the improving healthcare infrastructure, rising awareness, improving reimbursement scenario, and the growing insurance coverage in several APAC countries.
Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=39129877
Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Immucor, Inc. (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna (UK) are the players in this market.
Thermo Fisher Scientific (US) is one of the leading manufacturers of life science research and medical diagnostic products. The company focuses on launching technologically advanced products to maintain its leadership in the HLA typing industry. Furthermore, the company focuses on strengthening its revenue growth and brand positioning by adopting strategies such as acquisitions and expansions. Pertinent to this, Thermo Fisher Scientific acquired several companies to further enhance its presence in the market. These acquisitions enabled the company to expand and strengthen its product portfolio as well as develop innovative diagnostic technologies.